tiprankstipranks
Advertisement
Advertisement

HK:2509 Stock Latest News

Qyuns Therapeutics Swings to Profit on Surging 2025 Revenue and Stronger Balance Sheet
Company AnnouncementsQyuns Therapeutics Swings to Profit on Surging 2025 Revenue and Stronger Balance Sheet
13d ago
2509
Qyuns Therapeutics Forms Strategy and Development Committee to Sharpen Long-Term Planning
PremiumCompany Announcements
Qyuns Therapeutics Forms Strategy and Development Committee to Sharpen Long-Term Planning
13d ago
2509
Qyuns Therapeutics Tightens Audit Committee Mandate to Bolster Governance
PremiumCompany Announcements
Qyuns Therapeutics Tightens Audit Committee Mandate to Bolster Governance
13d ago
2509
Qyuns Therapeutics Sets Up Board Committee to Overhaul Executive Pay Oversight
PremiumCompany Announcements
Qyuns Therapeutics Sets Up Board Committee to Overhaul Executive Pay Oversight
13d ago
2509
Qyuns Therapeutics Sets Up Nomination Committee to Bolster Governance
PremiumCompany Announcements
Qyuns Therapeutics Sets Up Nomination Committee to Bolster Governance
13d ago
2509
Qyuns Therapeutics Invests RMB100 Million in Low-Risk Wealth Management Product
PremiumCompany AnnouncementsQyuns Therapeutics Invests RMB100 Million in Low-Risk Wealth Management Product
17d ago
2509
Qyuns Therapeutics Sets March Board Meeting to Approve 2025 Results and Consider Dividend
Premium
Company Announcements
Qyuns Therapeutics Sets March Board Meeting to Approve 2025 Results and Consider Dividend
23d ago
2509
Qyuns Therapeutics’ Ankylosing Spondylitis Drug Crusekitug Wins NDA Acceptance in China
Premium
Company Announcements
Qyuns Therapeutics’ Ankylosing Spondylitis Drug Crusekitug Wins NDA Acceptance in China
1M ago
2509
Qyuns Therapeutics Launches Share Buyback as Board Deems Stock Undervalued
PremiumCompany Announcements
Qyuns Therapeutics Launches Share Buyback as Board Deems Stock Undervalued
2M ago
2509
Qyuns Steps Up IBD Push as Caldera Raises US$112.5 Million and Starts Phase I Trial of Bispecific Antibody
PremiumCompany Announcements
Qyuns Steps Up IBD Push as Caldera Raises US$112.5 Million and Starts Phase I Trial of Bispecific Antibody
3M ago
2509
Qyuns Therapeutics Launches Share Buyback to Address Undervaluation Concerns
PremiumCompany Announcements
Qyuns Therapeutics Launches Share Buyback to Address Undervaluation Concerns
3M ago
2509
Qyuns Therapeutics Out-Licenses QX027N Globally in Deal Worth Up to US$700 Million
PremiumCompany Announcements
Qyuns Therapeutics Out-Licenses QX027N Globally in Deal Worth Up to US$700 Million
4M ago
2509
Qyuns Therapeutics Shareholders Approve Renewal of Caps for Connected Transactions at EGM
PremiumCompany AnnouncementsQyuns Therapeutics Shareholders Approve Renewal of Caps for Connected Transactions at EGM
4M ago
2509
Qyuns Therapeutics Advances Global Clinical Trials with Key Approval
Premium
Company Announcements
Qyuns Therapeutics Advances Global Clinical Trials with Key Approval
4M ago
2509
Qyuns Therapeutics Announces EGM to Discuss Key Resolutions
Premium
Company Announcements
Qyuns Therapeutics Announces EGM to Discuss Key Resolutions
4M ago
2509
Qyuns Therapeutics Announces EGM and H Shares Register Closure
PremiumCompany Announcements
Qyuns Therapeutics Announces EGM and H Shares Register Closure
4M ago
2509
Qyuns Therapeutics’ QX027N Antibody Gains Clinical Trial Approvals
PremiumCompany Announcements
Qyuns Therapeutics’ QX027N Antibody Gains Clinical Trial Approvals
5M ago
2509
Qyuns Therapeutics Renews Annual Caps for QX001S Framework Agreement
PremiumCompany Announcements
Qyuns Therapeutics Renews Annual Caps for QX001S Framework Agreement
5M ago
2509
Qyuns Therapeutics Initiates Share Repurchase to Boost Market Confidence
PremiumCompany Announcements
Qyuns Therapeutics Initiates Share Repurchase to Boost Market Confidence
5M ago
2509
Qyuns Therapeutics Partners with Roche for Global Development of QX031N
PremiumCompany AnnouncementsQyuns Therapeutics Partners with Roche for Global Development of QX031N
5M ago
2509
Qyuns Therapeutics Announces Promising Phase III Results for Ankylosing Spondylitis Treatment
Premium
Company Announcements
Qyuns Therapeutics Announces Promising Phase III Results for Ankylosing Spondylitis Treatment
5M ago
2509
Qyuns Therapeutics’ Subsidiary Achieves EU QP Certification, Paving Way for Global Expansion
Premium
Company Announcements
Qyuns Therapeutics’ Subsidiary Achieves EU QP Certification, Paving Way for Global Expansion
6M ago
2509

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >